Vaccines and diagnostics for novel porcine orthoreoviruses

26:

• A vaccine that confers immunity to a Porcine Orthoreovirus type 3-Virginia Tech (POV3-VT) strain, wherein the POV3-VT strain is characterized by having a 1 capsid protein with at least 98% sequence homology to the σ1 capsid protein represented by SEQ ID NO:20, and wherein the vaccine comprises an immunogenic amount of one or more type specific POV3-VT proteins present a live attenuated virus or a killed virus.

27:

• The vaccine of claim 26, wherein the vaccine comprises a live attenuated virus that is developed by passage of the POV3-VT strain in a non-porcine host until the passaged virus is capable of conferring immunity when inoculated into pigs but incapable of causing epidemic diarrhea.

28:

• A subunit vaccine that confers immunity to a Porcine Orthoreovirus type 3-Virginia Tech (POV3-VT) strain, wherein the POV3-VT strain is characterized by having a σ1 capsid protein with at least 98% sequence homology to the σ1 capsid protein represented by SEQ ID NO:20, and wherein the subunit vaccine comprises an immunogenic amount of one or more type specific POV3-VT proteins, or immunogenic portions thereof, produced in a bacterial or baculovirus expression system.

29:

• The vaccine of claim 28, wherein one or more type specific POV3-VT proteins or immunogenic portions comprise σ1 or σ1s proteins.

30:

• The vaccine of claim 29, further comprising at least one additional POV3-VT protein or immunogenic portion thereof wherein the protein is selected from the group consisting of σ2, σ3, σ4, λ1, λ2, λ3, μ1, μ2 and μ3 proteins.

31:

• A method of immunizing a pig against a Porcine Orthoreovirus type 3-Virginia Tech (POV3-VT) viral infection comprising administering to the pig an immunologically effective amount of a vaccine according to claim 26.

32:

• A method of immunizing a pig against a Porcine Orthoreovirus type 3-Virginia Tech (POV3-VT) viral infection comprising administering to the pig an immunologically effective amount of a vaccine according to claim 28.

34:

• The method of claim 33, wherein the antibody-based technique capable of detecting the specific binding of the antibody to the polypeptide comprises a technique selected from the group consisting of:
• an immunohistochemistry assay, a radioimmunoassay, an ELISA (enzyme linked immunosorbant assay), a sandwich immunoassay, an immuno-radiometric assay, a gel diffusion precipitation reaction, a immunodiffusion assay, an in situ immunoassay, a Western blot, a precipitation reaction, an agglutination assay, a complement fixation assays, a immunofluorescence assay, a protein A assay, and an immunoelectrophoresis assay.

35:

• A process of detecting a Porcine Orthoreovirus type 3-Virginia Tech (POV3-VT) virus strain in a biological sample comprising amplifying all or a strain specific portion of a POV3-VT nucleotide sequence under conditions suitable for a polymerase chain reaction and determining a presence of amplified POV3-VT nucleic acids in the sample, wherein the POV3-VT virus strain is characterized by having σ1 capsid protein that has at least 98% sequence homology to SEQ ID NO:20.

37:

• The process of claim 36, further comprising amplifying an L1 segment of the POV3-VT using L1 primers homologous to regions within the L1 segment of POV3-VT under conditions suitable for a polymerase chain reaction, and measuring the amplification product to detect POV3-VT in the biological sample.

39:

• The process of claim 35, comprising amplifying an S1 segment of POV3-VT or a strain specific fragment thereof and at least one additional POV3-VT segment selected from the group consisting of S2, S3, S4, L1, L2, L3, M1, M2 and M3 segments or a fragment thereof, each amplification using forward and reverse primers homologous to regions within each respective segment of POV3-VT under conditions suitable for a polymerase chain reaction;
• and detecting the amplification products to detect POV3-VT in the biological sample.

40:

• The process of claim 35, wherein the biological sample is a feed supplement.

41:

• The process of claim 35, wherein the nucleic acids in the sample are amplified using POV3-VT strain specific primers by polymerase chain reaction (PCR), real-time PCR, reverse transcriptase-polymerase chain reaction (RT-PCR), real-time reverse transcriptase-polymerase chain reaction (rt RT-PCR), quantitative real-time polymerase chain reaction (qRT-PCR), ligase chain reaction, or transcription-mediated amplification (TMA).

42:

• The process of claim 41, wherein a positive detection of POV3-VT is obtained by an amplification cycle threshold (CT) value exceeding background.

43:

• The process of claim 35, wherein the determining a presence of amplified POV3-VT nucleic acids in the sample comprises contacting the amplified nucleic acids with a probe comprising a nucleotide sequence having at least 98% sequence homology with SEQ. ID. NO:
• 19 and detecting hybridization between the amplified nucleic acids and the probe.

44:

• The process of claim 43, wherein the probe comprises a label selected from a radiolabel, fluorescent label, biotin label, enzymatic label, or a chemical label.